Masatoshi Kudo1, Kazuomi Ueshima1, Yukio Osaki2, Masashi Hirooka3, Yasuharu Imai4, Kazunobu Aso5, Kazushi Numata6, Masayuki Kitano7, Takashi Kumada8, Namiki Izumi9, Yasukiyo Sumino10, Chikara Ogawa11, Kohei Akazawa12. 1. Department of Gastroenterology and Hepatology, Kindai University School of Medicine, Osaka, Japan. 2. Department of Gastroenterology and Hepatology, Osaka Red Cross Hospital, Osaka, Japan. 3. Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Ehime, Japan. 4. Department of Gastroenterology, Ikeda Municipal Hospital, Osaka, Japan. 5. Division of Metabolism and Biosystemic Science, Department of Internal Medicine, Asahikawa Medical College, Asahikawa, Japan. 6. Gastroenterological Center, Yokohama City University Medical Center, Yokohama, Japan. 7. Second Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan. 8. Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Ogaki, Japan. 9. Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Musashino, Japan. 10. Division of Gastroenterology and Hepatology, Department of Internal Medicine, Toho University Medical Center, Tokyo, Japan. 11. Department of Gastroenterology and Hepatology, Takamatsu Red Cross Hospital, Takamatsu, Japan. 12. Department of Medical Informatics, Niigata University Medical and Dental Hospital, Niigata City, Japan.
Abstract
BACKGROUND: Current practice guidelines recommend the use of ultrasound (US) as an initial surveillance tool for hepatocellular carcinoma (HCC) in patients with liver cirrhosis. Patients with liver cirrhosis, however, frequently have coarse liver parenchyma, masking the presence of tiny nodules during B-mode US. Contrast-enhanced US (CEUS) with Sonazoid has a long-lasting, stable Kupffer phase, which makes it possible to scan the entire liver to depict small lesions. In addition, defect reperfusion imaging (reinjection imaging) enables to determine whether the detected nodule is HCC or not. This prospective, multicenter, randomized, controlled trial was conducted to demonstrate the usefulness of Kupffer phase surveillance in the detection of small HCC compared to B-mode US. METHODS: A total of 23 institutions joined this study. In total, 656 patients with hepatitis B- or C-related liver cirrhosis were randomized either to the B-mode US surveillance group (n = 313) or the Kupffer phase CEUS with Sonazoid surveillance group (n = 309). The primary endpoint was the maximum size of HCC at the time of the first detection. Secondary endpoints included time to HCC detection, number of tumors, and Barcelona Clinic Liver Cancer stage at the first detection, and sensitivity, specificity, and accuracy of each method in the diagnosis, and the cumulative detection rate of HCC. RESULTS: The mean HCC size at the first detection was significantly smaller in the CEUS (13.0 ± 4.1 mm; n = 28) than in the B-mode US group (16.7 ± 4.1 mm; n = 26) (p = 0.011). Of the 38 patients with HCV cirrhosis diagnosed with HCC by US alone, mean tumor size at the first detection was significantly smaller in the 20 patients diagnosed by CEUS alone than in the 18 diagnosed by B-mode US alone (12.7 ± 3.1 vs. 17.6 ± 7.0 mm, p = 0.012). In contrast, among the 16 patients with HBV cirrhosis diagnosed by US alone, mean tumor size at the first detection was similar in the 8 patients diagnosed by CEUS alone and the 8 diagnosed by B-mode US (13.6 ± 6.0 vs. 14.5 ± 2.7 mm, p = 0.715). CONCLUSION: Kupffer phase CEUS surveillance with Sonazoid is extremely useful for the early detection and confirmation of HCC using a reinjection technique. Kupffer phase CEUS with Sonazoid contrast combined with the reinjection technique is, therefore, recommended as first-line screening tool for HCC in patients with liver cirrhosis, especially those with very coarse liver parenchyma.
BACKGROUND: Current practice guidelines recommend the use of ultrasound (US) as an initial surveillance tool for hepatocellular carcinoma (HCC) in patients with liver cirrhosis. Patients with liver cirrhosis, however, frequently have coarse liver parenchyma, masking the presence of tiny nodules during B-mode US. Contrast-enhanced US (CEUS) with Sonazoid has a long-lasting, stable Kupffer phase, which makes it possible to scan the entire liver to depict small lesions. In addition, defect reperfusion imaging (reinjection imaging) enables to determine whether the detected nodule is HCC or not. This prospective, multicenter, randomized, controlled trial was conducted to demonstrate the usefulness of Kupffer phase surveillance in the detection of small HCC compared to B-mode US. METHODS: A total of 23 institutions joined this study. In total, 656 patients with hepatitis B- or C-related liver cirrhosis were randomized either to the B-mode US surveillance group (n = 313) or the Kupffer phase CEUS with Sonazoid surveillance group (n = 309). The primary endpoint was the maximum size of HCC at the time of the first detection. Secondary endpoints included time to HCC detection, number of tumors, and Barcelona Clinic Liver Cancer stage at the first detection, and sensitivity, specificity, and accuracy of each method in the diagnosis, and the cumulative detection rate of HCC. RESULTS: The mean HCC size at the first detection was significantly smaller in the CEUS (13.0 ± 4.1 mm; n = 28) than in the B-mode US group (16.7 ± 4.1 mm; n = 26) (p = 0.011). Of the 38 patients with HCV cirrhosis diagnosed with HCC by US alone, mean tumor size at the first detection was significantly smaller in the 20 patients diagnosed by CEUS alone than in the 18 diagnosed by B-mode US alone (12.7 ± 3.1 vs. 17.6 ± 7.0 mm, p = 0.012). In contrast, among the 16 patients with HBV cirrhosis diagnosed by US alone, mean tumor size at the first detection was similar in the 8 patients diagnosed by CEUS alone and the 8 diagnosed by B-mode US (13.6 ± 6.0 vs. 14.5 ± 2.7 mm, p = 0.715). CONCLUSION: Kupffer phase CEUS surveillance with Sonazoid is extremely useful for the early detection and confirmation of HCC using a reinjection technique. Kupffer phase CEUS with Sonazoid contrast combined with the reinjection technique is, therefore, recommended as first-line screening tool for HCC in patients with liver cirrhosis, especially those with very coarse liver parenchyma.
Authors: Michel Claudon; Christoph F Dietrich; Byung Ihn Choi; David O Cosgrove; Masatoshi Kudo; Christian P Nolsøe; Fabio Piscaglia; Stephanie R Wilson; Richard G Barr; Maria C Chammas; Nitin G Chaubal; Min-Hua Chen; Dirk Andre Clevert; Jean Michel Correas; Hong Ding; Flemming Forsberg; J Brian Fowlkes; Robert N Gibson; Barry B Goldberg; Nathalie Lassau; Edward L S Leen; Robert F Mattrey; Fuminori Moriyasu; Luigi Solbiati; Hans-Peter Weskott; Hui-Xiong Xu Journal: Ultrasound Med Biol Date: 2012-11-05 Impact factor: 2.998
Authors: Hager A Ahmed Mohammed; Ju Dong Yang; Nasra H Giama; Jonggi Choi; Hawa M Ali; Kristin C Mara; William S Harmsen; Russell H Wiesner; Michael D Leise; Terry M Therneau; Lewis R Roberts Journal: Liver Cancer Date: 2016-12-17 Impact factor: 11.740
Authors: Jorge A Marrero; Laura M Kulik; Claude B Sirlin; Andrew X Zhu; Richard S Finn; Michael M Abecassis; Lewis R Roberts; Julie K Heimbach Journal: Hepatology Date: 2018-08 Impact factor: 17.425
Authors: Mohammed Eslam; Shiv K Sarin; Vincent Wai-Sun Wong; Jian-Gao Fan; Takumi Kawaguchi; Sang Hoon Ahn; Ming-Hua Zheng; Gamal Shiha; Yusuf Yilmaz; Rino Gani; Shahinul Alam; Yock Young Dan; Jia-Horng Kao; Saeed Hamid; Ian Homer Cua; Wah-Kheong Chan; Diana Payawal; Soek-Siam Tan; Tawesak Tanwandee; Leon A Adams; Manoj Kumar; Masao Omata; Jacob George Journal: Hepatol Int Date: 2020-10-01 Impact factor: 6.047
Authors: Julie Y An; Miguel A Peña; Guilherme M Cunha; Michael T Booker; Bachir Taouli; Takeshi Yokoo; Claude B Sirlin; Kathryn J Fowler Journal: Radiographics Date: 2020 Nov-Dec Impact factor: 5.333